List of Excipients in Branded Drug TRICOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	TRICOR	fenofibrate	0074-3173	CELLULOSE, MICROCRYSTALLINE
AbbVie Inc	TRICOR	fenofibrate	0074-3173	CROSPOVIDONE
AbbVie Inc	TRICOR	fenofibrate	0074-3173	D&C YELLOW NO. 10
AbbVie Inc	TRICOR	fenofibrate	0074-3173	DOCUSATE SODIUM
AbbVie Inc	TRICOR	fenofibrate	0074-3173	FD&C BLUE NO. 2
AbbVie Inc	TRICOR	fenofibrate	0074-3173	FD&C YELLOW NO. 6

Tricor Excipient Strategy and Commercial Opportunities for Fenofibrate Products

Last updated: August 9, 2026

Tricor is the branded fenofibrate product historically marketed by Abbott Laboratories and later AbbVie for hypertriglyceridemia and mixed dyslipidemia. Its commercial differentiation depended largely on fenofibrate particle size, dissolution behavior, and food-effect control rather than on a novel active ingredient. The principal excipient opportunities now are improved bioavailability, lower food dependence, patient-friendly dosage forms, and differentiated generic or reformulated products.

Fenofibrate is a poorly water-soluble compound. Its formulation performance depends on particle engineering, wetting, surfactant selection, granulation, and control of solid-state properties. Generic competition has reduced the value of simple tablet substitution, but formulation platforms that provide reliable exposure under fed and fasting conditions can still support premium positioning, 505(b)(2) strategies, licensing, or technology supply agreements.

What is Tricor and how does its formulation work?

Tricor contains fenofibrate, a fibric acid derivative used to reduce triglycerides and increase high-density lipoprotein cholesterol in specified dyslipidemia populations. The product has been marketed in 48 mg and 145 mg tablet strengths in the United States.

Fenofibrate has low aqueous solubility. The formulation must improve dissolution in the gastrointestinal tract so that the active ingredient can be absorbed. Earlier fenofibrate products had clinically meaningful food effects, while later formulations were designed to reduce dependence on meal composition and fat content.

The commercial formulation levers are:

Formulation lever	Commercial purpose
Micronization	Increases surface area and dissolution rate
Controlled particle-size distribution	Reduces batch variability and supports bioequivalence
Surfactants and wetting agents	Improve contact between fenofibrate and gastrointestinal fluids
Disintegrants	Accelerate tablet breakup and drug release
Hydrophilic binders	Improve granulation and dispersion
Lipid-based excipients	Support solubilization of poorly soluble fenofibrate
Coating systems	Improve swallowability, stability, and product appearance
Functional excipients	Control release or provide food-effect mitigation

The FDA-approved Tricor label identifies conventional pharmaceutical excipients used in tablet manufacture, including lactose, crospovidone, microcrystalline cellulose, hypromellose, magnesium stearate, sodium lauryl sulfate, sucrose, and colloidal silicon dioxide, depending on product strength and presentation [1].

What excipients are used in Tricor tablets?

Tricor tablets use a conventional solid oral formulation architecture combined with particle-size reduction of fenofibrate. The excipients support powder flow, tablet compression, wetting, disintegration, coating, and physical stability.

Core excipient functions

Excipient category	Typical function in a fenofibrate tablet
Lactose monohydrate	Diluent and compression aid
Microcrystalline cellulose	Diluent, binder, and tablet-strength contributor
Crospovidone	Superdisintegrant
Sodium lauryl sulfate	Wetting and dissolution aid
Hypromellose	Film former and coating polymer
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and moisture-management aid
Sucrose	Coating or formulation aid in certain presentations

The specific qualitative and quantitative composition must be confirmed against the applicable FDA label and manufacturer-controlled product documentation. Generic fenofibrate tablets do not necessarily use the same excipients as Tricor. Their regulatory objective is pharmaceutical equivalence and bioequivalence, not excipient matching.

Why sodium lauryl sulfate matters

Sodium lauryl sulfate can improve wetting of hydrophobic fenofibrate particles. Its value depends on concentration, compatibility with the formulation, and its effect on dissolution across physiologic media. Excessive surfactant levels can create manufacturing, tolerability, or stability problems.

Potential substitutes include polysorbates, poloxamers, sodium docusate, and other surfactants. These materials can create a differentiated formulation, but substitution alone usually has limited commercial defensibility unless it produces a measurable improvement in dissolution, food-effect performance, stability, or manufacturing yield.

How does fenofibrate particle engineering affect excipient strategy?

Particle engineering is the central formulation issue for Tricor and competing fenofibrate products. Micronization reduces particle size and increases surface area, but it does not eliminate the need for suitable wetting, dispersion, and tablet disintegration.

Critical quality attributes include:

• Particle-size distribution, including d10, d50, and d90 values
• Specific surface area
• Crystal form and polymorphic stability
• Surface energy and agglomeration tendency
• Moisture content
• Dissolution profile in biorelevant media
• Content uniformity at low tablet strength
• Blend segregation and flowability

A small particle size can increase dissolution while worsening powder flow, electrostatic charging, agglomeration, and blend uniformity. Excipients such as colloidal silicon dioxide, microcrystalline cellulose, and surfactants can offset those manufacturing risks, but the final design must balance dissolution against process robustness.

Commercial opportunity: particle-engineering platforms

A supplier with a reproducible micronization, nanocrystal, spray-drying, or co-processing platform could license the technology to generic manufacturers. The strongest commercial case would combine:

1. A demonstrable dissolution advantage.
2. Reduced variability across manufacturing lots.
3. A scalable process compatible with existing tablet equipment.
4. A path to bioequivalence without extensive clinical development.
5. Protection through process, composition, or performance claims.

A simple micronized-fenofibrate product is unlikely to support significant premium pricing because multiple generic products already use particle-size reduction and conventional excipients.

What formulation patents protected Tricor and related fenofibrate products?

Fenofibrate product protection historically included formulation, particle-size, dissolution, and method-of-use claims. The core compound patent and early formulation rights have expired or are no longer sufficient to block ordinary generic competition in the United States.

Fenofibrate product litigation in the United States involved challenges to Abbott's and later AbbVie's patents covering formulations and dosing presentations. The most commercially important disputes concerned generic products seeking approval under abbreviated new drug applications and asserting Paragraph IV invalidity or non-infringement positions.

The relevant patent categories were:

Patent category	Scope commonly pursued
Micronized fenofibrate	Particle-size and dissolution performance
Tablet composition	Fenofibrate plus excipient combinations
Food-effect reduction	Formulations intended to provide exposure with or without food
Dosage strength	48 mg and 145 mg presentations
Manufacturing process	Milling, granulation, blending, and compression
Method of use	Treatment of hypertriglyceridemia or mixed dyslipidemia

The current commercial barrier is therefore not the existence of a single blocking Tricor patent. It is the combined technical challenge of reproducing bioavailability, controlling manufacturing variability, and obtaining FDA approval.

What is the Orange Book status of Tricor?

Tricor is an FDA-approved prescription drug product with historical Orange Book-listed patents and exclusivity information. The product has faced generic competition, and fenofibrate tablets and capsules are available from multiple manufacturers.

Orange Book analysis should distinguish between:

• The current reference-listed drug status.
• Patents historically listed for Tricor.
• Patents listed for other fenofibrate reference products.
• Approved generic dosage forms and strengths.
• Whether a listed patent remains enforceable or has expired.
• Whether a patent applies to the exact dosage form under review.

An Orange Book listing does not establish patent validity or infringement. A generic applicant may submit a Paragraph IV certification, a Section VIII statement for a method-of-use patent, or another certification permitted by the Hatch-Waxman framework. FDA approval timing can also depend on litigation, 30-month stays, exclusivity, and the specific reference product.

When did Tricor lose exclusivity and what generic entry risks remain?

Tricor's principal market exclusivity has ended, and generic fenofibrate products compete in the United States. The relevant commercial risk is now product-level substitution rather than first generic entry.

Generic entry risks include:

Risk	Impact on branded or differentiated products
Price erosion	Reduces reimbursement and pharmacy acquisition economics
Therapeutic substitution	Moves prescriptions to other fenofibrate formulations
Formulary exclusion	Limits access to branded products
Authorized generic competition	Compresses first-mover generic margins
Multiple ANDA approvals	Creates rapid price competition
Product-specific bioequivalence	Can delay or prevent certain generic launches
Supply-chain disruption	Creates temporary opportunities for alternative suppliers

A generic manufacturer can compete without copying every Tricor excipient. FDA approval generally requires the applicant to demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. The generic can use different inactive ingredients when the formulation meets regulatory requirements and does not create unacceptable safety or performance differences [2].

Which fenofibrate products compete with Tricor?

The competitive field includes generic fenofibrate tablets and capsules, as well as branded or historically branded formulations such as Triglide, Antara, Lipofen, and Fenoglide. These products used different approaches to particle size, delivery system, dosage form, and food-effect management.

Product or product class	Differentiation historically emphasized
Tricor	Micronized fenofibrate tablets and improved absorption relative to older products
Triglide	Microcoated or particle-engineered delivery approach
Antara	Micronized fenofibrate capsule formulation
Lipofen	Fenofibrate capsule product
Fenoglide	Tablet formulation using a bioavailability-oriented delivery system
Generic fenofibrate	Lower cost and regulatory equivalence

The strongest competitive comparison is not brand versus generic alone. It is formulation platform versus formulation platform. A product that reduces food restrictions, improves adherence, or provides more consistent exposure may have commercial value even in a genericized market, but the benefit must be clinically and economically visible.

What new excipient strategies could create commercial opportunities?

1. Food-effect mitigation

Food dependence remains a relevant patient and prescribing issue. A formulation that delivers consistent exposure under fed and fasting conditions could support a 505(b)(2) or lifecycle-management strategy if the sponsor can establish a meaningful clinical or regulatory distinction.

Relevant excipients include:

• Surfactant systems
• Lipidic vehicles
• Self-emulsifying drug-delivery systems
• Amphiphilic polymers
• Solubilizing agents
• Co-processed excipient systems

The primary development risk is that improved dissolution in vitro may not translate into a clinically meaningful reduction in food effect.

2. Lipid-based delivery

Fenofibrate is a logical candidate for lipid-based formulation because of its poor water solubility. Soft-gel capsules, self-emulsifying systems, and lipid suspensions can improve apparent solubilization.

Commercial advantages may include:

• Reduced particle-size dependence
• Improved dispersion after administration
• Potentially lower food sensitivity
• Flexible capsule manufacturing

Risks include fill-volume constraints, capsule-shell compatibility, oxidation, leakage, excipient tolerability, and more complex stability programs.

3. Nanocrystal or nanosuspension systems

Nanocrystal technology can increase dissolution rate without requiring a large amount of surfactant. Stabilizers such as polymers and surfactants maintain particle dispersion.

Potential barriers include:

• Agglomeration during storage
• Scale-up complexity
• High-pressure homogenization or milling costs
• Solid-state changes
• More demanding process controls

A nanocrystal product may be attractive for a differentiated prescription product, but the commercial case depends on proving a benefit over established micronized generic products.

4. Abuse-resistant or patient-friendly dosage forms

Abuse resistance is not a major commercial driver for fenofibrate. Patient-friendly features are more relevant:

• Smaller tablets
• Once-daily dosing
• Easier swallowing
• Reduced tablet weight
• Lower lactose content
• Vegetarian or gelatin-free capsules
• Improved stability in high-humidity environments

These features can support niche products, tenders, hospital contracts, and international licensing even when they do not justify a U.S. premium brand.

5. Combination products

A fenofibrate combination with a statin or another lipid-lowering agent could improve adherence, but the development program would require careful assessment of drug-drug interactions, dosing flexibility, and cardiovascular outcome positioning.

Excipient opportunities include bilayer tablets, fixed-dose multiparticulates, or physically separated drug layers. The principal barrier is regulatory and clinical rather than excipient-related. A combination product requires evidence that the fixed doses are appropriate and that the risk-benefit profile is acceptable.

How strong is the patent estate for a new fenofibrate excipient platform?

A new fenofibrate excipient platform can obtain patent protection, but broad composition claims may be difficult because fenofibrate has been extensively formulated.

Potentially defensible claim types include:

• Defined particle-size distributions
• Specific excipient ratios
• Dissolution thresholds
• Reduced food-effect performance
• Manufacturing processes
• Stable amorphous or co-crystal forms
• Capsule fill compositions
• Multiparticulate structures
• Specific packaging and moisture-control systems

Patent strength improves when the formulation produces an unexpected result, such as a substantial reduction in food effect, a stability improvement, or a bioavailability profile not predictable from routine formulation optimization.

A patent that claims only fenofibrate plus a common disintegrant or surfactant is likely to face substantial validity and obviousness risk. Process patents can remain commercially useful when the manufacturing process is difficult to detect or replicate, but enforcement is harder if the process is not publicly observable.

What FDA regulatory pathway applies to new Tricor formulation opportunities?

The pathway depends on the intended commercial position.

Product strategy	Likely pathway
Conventional generic tablet	ANDA under Section 505(j)
Reformulated product with clinical differentiation	505(b)(2) NDA
New fixed-dose combination	505(b)(2) or full NDA, depending on reliance and data
New dosage form with limited reliance	505(b)(2)
OTC switch	NDA or supplemental NDA with additional evidence
Foreign-market product	National procedures under the applicable jurisdiction

An ANDA is usually the lowest-cost route but provides limited room for clinical differentiation. A 505(b)(2) application can support a new formulation, dosage form, strength, or dosing condition while relying partly on existing fenofibrate safety and efficacy information. It generally requires more evidence than an ANDA, particularly when the sponsor claims a clinically relevant change in exposure, food effect, or dosing.

What commercial opportunities exist for excipient suppliers?

The most practical opportunities are upstream and platform-based rather than the launch of another undifferentiated fenofibrate tablet.

High-potential opportunities

1. Co-processed excipient systems that improve flow and content uniformity for micronized fenofibrate.
2. Surfactant-polymer combinations that improve wetting without excessive surfactant loading.
3. Lipid-based capsule systems for reduced food effect.
4. Nanocrystal stabilizer packages compatible with high-throughput manufacturing.
5. Moisture-resistant coatings and packaging for hot and humid markets.
6. Low-lactose or lactose-free platforms for differentiated generic products.
7. Technology licensing to regional manufacturers seeking bioequivalent fenofibrate products.
8. Contract development and manufacturing for 505(b)(2) lifecycle products.

Lower-potential opportunities

Commodity lactose, magnesium stearate, and standard microcrystalline cellulose have limited strategic value unless bundled with a validated formulation platform. A supplier should compete on performance data, process integration, regulatory support, and supply reliability rather than on excipient identity alone.

What manufacturing and intellectual-property barriers affect fenofibrate products?

Manufacturing barriers include consistent micronization, powder handling, low-dose blend uniformity, surfactant distribution, tablet hardness, dissolution control, and prevention of particle agglomeration.

Intellectual-property barriers are more likely to arise from:

• Specific formulation architecture
• Manufacturing know-how
• Bioequivalence-sensitive performance parameters
• New polymorphs or solid forms
• Delivery systems that reduce food effect
• Combination-product claims

Geographic strategy also matters. U.S. patent and FDA requirements differ from those in the European Union, Canada, Japan, China, and emerging markets. A formulation with limited U.S. exclusivity potential may still be commercially valuable in countries where branded fenofibrate products retain stronger pricing or where local manufacturing capacity is limited.

How does Tricor compare with broader poorly soluble-drug opportunities?

Fenofibrate is technically accessible because it has a long clinical history and well-established safety profile. That lowers active-pharmaceutical-ingredient risk. It also limits differentiation because generic manufacturers and formulation developers have extensive prior art and commercial experience.

Factor	Fenofibrate opportunity
Clinical risk	Low relative to a new chemical entity
Formulation risk	Moderate
Patent breadth	Limited for routine tablet formulations
Generic competition	High
Need for clinical differentiation	Moderate to high for premium products
Excipient platform potential	Moderate
Licensing potential	Stronger outside the U.S. or in specialized delivery systems
Revenue upside	Limited for commodity generics; higher for differentiated 505(b)(2) products

Key Takeaways

• Tricor's formulation value came primarily from fenofibrate particle engineering, dissolution control, and management of food-effect behavior.
• Conventional excipients such as lactose, microcrystalline cellulose, crospovidone, sodium lauryl sulfate, hypromellose, and magnesium stearate support the tablet but provide limited standalone differentiation.
• Generic fenofibrate competition has materially weakened the commercial value of an ordinary Tricor-equivalent tablet.
• The strongest remaining opportunities involve food-effect mitigation, lipid-based delivery, nanocrystals, patient-friendly dosage forms, and manufacturing platforms.
• A 505(b)(2) strategy offers more differentiation than an ANDA but requires stronger evidence and a commercially meaningful product claim.
• Patent protection is more credible for defined excipient systems, manufacturing processes, dissolution performance, and unexpected bioavailability results than for routine excipient substitutions.
• Excipient suppliers are better positioned to commercialize validated delivery platforms than to sell commodity ingredients alone.
• There is no biosimilar pathway for fenofibrate because it is a small-molecule drug, not a biologic.

FAQs

Can a new excipient combination obtain patents around fenofibrate?

Yes. Protection may be available for defined compositions, excipient ratios, manufacturing methods, dissolution profiles, solid forms, or reduced-food-effect performance. Routine combinations of fenofibrate with well-known excipients face greater obviousness risk.

Is fenofibrate suitable for a self-emulsifying drug-delivery system?

Fenofibrate is technically suitable because of its poor water solubility. Development must address lipid excipient tolerability, oxidation, capsule compatibility, precipitation after dilution, and stability.

Would a lactose-free fenofibrate tablet have meaningful commercial value?

It could support a niche differentiated product, particularly where lactose avoidance, tablet size, or excipient labeling affects purchasing decisions. Lactose removal alone is unlikely to support substantial U.S. premium pricing.

Can an excipient supplier obtain a royalty from a generic fenofibrate manufacturer?

Yes, if the supplier controls a protected formulation or manufacturing platform that materially supports approval, bioequivalence, or product performance. Commodity excipient supply generally does not create meaningful royalty leverage.

Does fenofibrate have biosimilar competition?

No. Fenofibrate is a small molecule approved through conventional drug pathways. Competition occurs through generic and reformulated products, including ANDA and potentially 505(b)(2) products.

References

1. U.S. Food and Drug Administration. (2024). Tricor (fenofibrate) tablets, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2019). ANDAs for certain highly soluble, highly permeable, and rapidly dissolving drug products. Guidance for industry. https://www.fda.gov/

5. European Medicines Agency. (2010). Guideline on the investigation of bioequivalence. https://www.ema.europa.eu/

6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355. https://uscode.house.gov/